Absence of Mutagenic Effects of Sodium Dichloroacetate
+ Author Affiliations1. Cypros Pharmaceutical Corporation 2732 Loker Avenue West, Carlsbad, California 92008 2. *corning Hazleton Inc 9200 Leesburg Pike, Vienna. Virginia 22182 3. †Consultant in Toxicology 3725 Ridgelea Drive, Fairfax. Virginia 22031
Received January 12, 1996.
Accepted March 20, 1996.
Sodium dichloroacetate (DCA) is a drug with potential for treating patients with stroke and head injury. Conflicting evidence has been published on the mutagenic potential of DCA. A series of genetic tests for mutagenicity and clastogenicity was carried out on pharmaceutical grade DCA. Four types of mutagenicity test were included, with and without metabolic activation where appropriate. These studies included: (i) Salmonella and Escherichia coli mutation (Ames) tests, (ii) thymidine kinase locus forward mutation in L5178Y mouse lymphoma cells, (iii) tests for chromosomal aberrations in Chinese hamster ovary cells, and (iv) an in vivo rat bone marrow erythroid micronucleus test. In each study, there was no evidence of mutagenic activity attributable to DCA. It is possible that the present test material, of pharmaceutical grade, has fewer impurities than materials studied in previous reports. These data extend, and in some cases contradict, previous published reports on DCA.